<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Resveratrol" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Resveratrol</book-part-id>
      <title-group>
        <title>Resveratrol</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>11</month>
          <year>2024</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Resmetirom" document-type="chapter">Resmetirom</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Retinoids" document-type="chapter">Retinoids</related-object>
    </book-part-meta>
    <body>
      <sec id="Resveratrol.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Resveratrol.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Resveratrol is a plant polyphenol found in high concentrations in red grapes that has been proposed as a treatment for hyperlipidemia and to prevent fatty liver, diabetes, atherosclerosis and aging. Resveratrol use has been associated with rare instances of serum enzyme elevations during therapy but has not been convincingly linked to episodes of clinically apparent liver injury.</p>
        </sec>
        <sec id="Resveratrol.Background">
          <title>Background</title>
          <p>Resveratrol is a natural plant polyphenol (3,5,4&#x02019;-trihydroxystilbene) that is found in highest concentrations in the skin of red grapes and other fruits (mulberries, blueberries, blackberries). In cell culture, resveratrol has antiinflammatory, cytoprotective, and antineoplastic properties which can be reproduced in several animal models. In model systems such as yeast (S. cerevisiae), worms (C. elegans), and fruit flies (Drosophila), chronic administration of resveratrol extends lifespan in a manner similar to caloric restriction. These results were somewhat controversial, but subsequent studies in several mammalian species supported the finding to some extent. Thus, resveratrol extended lifespan in mice fed a high fat diet (but not in normal mice), seemingly by counteracting the detrimental effects of the diet, and improving insulin sensitivity and mitochondrial function. The bases for the beneficial effects of resveratrol are unclear. Resveratrol has direct antioxidant effects, but also stimulates expression of antioxidant enzymes and the activity of sirtuin 1 (SIRT1) and adenosine monophosphate activated protein kinase (AMP-K), both of which have major effects on glucose and fat metabolism and may play a role in aging. Resveratrol is available without prescription as a nutritional supplement in multiple preparations and doses. In human trials, doses of resveratrol have ranged from 20 mg to 5 gm daily, but a typical over-the-counter recommended dose is 500 mg twice daily. Importantly, the purity of commercial products is rarely well defined, its oral bioavailability is poor and the component responsible for its activity is not known. Thus, resveratrol exists in both trans and cis configuration and the major form found in plasma is a sulfated or glucuronidal conjugate rather than free resveratrol. At present, there is no conclusive evidence that resveratrol has beneficial effects in humans. On the other hand, it has few if any side effects. Side effects may include minor gastrointestinal upset, nausea, headache and fatigue and possible supplement-drug interactions with estrogens and anticoagulants.</p>
        </sec>
        <sec id="Resveratrol.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>There have been multiple trials of resveratrol in human subjects, but the dose regimen and duration of therapy has varied greatly and many trials lacked information on adverse events, ALT elevations, and hepatotoxicity. Nevertheless, in most studies there was no mention of serum ALT elevations or only rare and mild-to-moderate increases that were asymptomatic and resolved rapidly upon stopping therapy. However, in studies using high doses of resveratrol (1.5 to 3.0 grams daily), average serum ALT and AST levels rose slightly during therapy and promptly fell into the normal range with stopping. There were, however, no instances of serum ALT elevations with jaundice or symptoms. Furthermore, despite widespread clinical use, there have been no published reports of clinically apparent liver injury attributed to resveratrol. In large case series and nationwide registries on herbal induced liver injury, resveratrol is not listed as a cause. Thus, hepatotoxicity due to resveratrol must be rare, if it occurs at all.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="HerbalDietarySuppl" document-type="book-part">Herbal and Dietary Supplements</related-object></p>
        </sec>
      </sec>
      <sec id="Resveratrol.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Resveratrol &#x02013; Generic</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Herbal and Dietary Supplements</p>
        <p>
<bold>SUMMARY INFORMATION</bold>
</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nlm.nih.gov/medlineplus/druginfo/natural/307.html">Fact Sheet at MedlinePlus, NLM</ext-link>
</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Resveratrol">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Resveratrol.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Resveratrol.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <tbody>
              <tr>
                <th id="hd_b_Resveratrol.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_b_Resveratrol.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_b_Resveratrol.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_b_Resveratrol.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
              <tr>
                <td headers="hd_b_Resveratrol.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Resveratrol</td>
                <td headers="hd_b_Resveratrol.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135024495">501-36-0</ext-link>
</td>
                <td headers="hd_b_Resveratrol.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C14-H12-O3</td>
                <td headers="hd_b_Resveratrol.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135024495" document-id-type="sid" document-type="summary" object-id="135024495" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Resveratrol.ANNOTATED_SELECTIVE_BIBLIOGR">
        <title>ANNOTATED SELECTIVE BIBLIOGRAPHY</title>
        <p>References updated: 30 November 2024</p>
        <p>Abbreviations used: HDS, herbal and dietary supplements.</p>
        <ref-list id="Resveratrol.ANNOTATED_SELECTIVE_BIBLIOGR.reflist0">
          <ref id="Resveratrol.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Unconventional drugs. Miscellaneous drugs and diagnostic chemicals. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 731-4.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999; several herbal medications are discussed, but not resveratrol).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.seeff.2013">
            <mixed-citation publication-type="book">Seeff L, Stickel F, Navarro VJ. Hepatotoxicity of herbals and dietary supplements. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, p. 631-58.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of herbal and dietary supplements; no mention of resveratrol).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Resveratrol.REF3">
            <mixed-citation publication-type="book">Resveratrol. In, PDR for Herbal Medicines. 4th ed. Montvale, New Jersey: Thomson Healthcare Inc. 2007: pp. 19-26.<annotation><p><italic toggle="yes">(Compilation of short monographs on herbal medications and dietary supplements).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.stedman.2002.195">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Stedman</surname>
<given-names>C.</given-names></string-name>
<article-title>Herbal hepatotoxicity.</article-title>
<source>Semin Liver Dis</source>
<year>2002</year>; <volume>22</volume>: <fpage>195</fpage>-<lpage>206</lpage>.<annotation><p><italic toggle="yes">(Review and description of patterns of liver injury, including discussion of potential risk factors, and herb-drug interactions).</italic></p></annotation><pub-id pub-id-type="pmid">12016550</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.schiano.2003.453">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Schiano</surname>
<given-names>TD</given-names></string-name>. <article-title>Hepatotoxicity and complementary and alternative medicines.</article-title>
<source>Clin Liver Dis</source>
<year>2003</year>; <volume>7</volume>: <fpage>453</fpage>-<lpage>73</lpage>.<annotation><p><italic toggle="yes">(Comprehensive review of herbal associated hepatotoxicity, including common patterns of presentation).</italic></p></annotation><pub-id pub-id-type="pmid">12879994</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.baur.2006.337">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Baur</surname>
<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname>
<given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Price</surname>
<given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Jamieson</surname>
<given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Lerin</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kalra</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Prabhu</surname>
<given-names>VV</given-names></string-name>, <etal>et al.</etal>
<article-title>Resveratrol improves health and survival of mice on a high-calorie diet.</article-title>
<source>Nature</source>
<year>2006</year>; <volume>444</volume>: <fpage>337</fpage>-<lpage>42</lpage>.<annotation><p><italic toggle="yes">(In mice fed a high caloric diet long term, resveratrol [22 mg/kg/day] supplementation increased life span, improved insulin sensitivity, and decreased hepatic fat).</italic></p></annotation><pub-id pub-id-type="pmid">17086191</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.pfluger.2008.9793">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pfluger</surname>
<given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Herranz</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Velasco-Miguel</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Serrano</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tsch&#x000f6;p</surname>
<given-names>MH</given-names></string-name>. <article-title>Sirt1 protects against high-fat diet-induced metabolic damage.</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>2008</year>; <volume>105</volume>: <fpage>9793</fpage>-<lpage>8</lpage>.<annotation><p><italic toggle="yes">(Mice with overexpression of SIRT1 were protected from the metabolic effects of a high fat diet, and had improved insulin sensitivity and less hepatic fat and inflammation with lower levels of inflammatory cytokines and higher antioxidant enzymes).</italic></p></annotation><pub-id pub-id-type="pmid">18599449</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.chalasani.2008.1924">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chalasani</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Bonkovsky</surname>
<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Watkins</surname>
<given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Davern</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Serrano</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rochon</surname>
<given-names>J</given-names></string-name>; <collab>Drug Induced Liver Injury Network (DILIN)</collab>. <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
<source>Gastroenterology</source>
<year>2008</year>; <volume>135</volume>: <fpage>1924</fpage>-<lpage>34</lpage>.<annotation><p><italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, 9% of cases were attributed to herbal medications, but no case attributed to resveratrol alone or in combination with other agents).</italic></p></annotation><pub-id pub-id-type="pmid">18955056</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.garc_acort_s.2008.688">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Garc&#x000ed;a-Cort&#x000e9;s</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Borraz</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lucena</surname>
<given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Pel&#x000e1;ez</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Salmer&#x000f3;n</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Diago</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mart&#x000ed;nez-Sierra</surname>
<given-names>MC</given-names></string-name>, <etal>et al.</etal>
<comment>[Liver injury induced by "natural remedies": an analysis of cases submitted to the Spanish Liver Toxicity Registry]</comment>. <source>Rev Esp Enferm Dig</source>
<year>2008</year>; <volume>100</volume>: <fpage>688</fpage>-<lpage>95</lpage>. <comment>Spanish.</comment><annotation><p><italic toggle="yes">(Among 521 cases of drug induced liver injury submitted to Spanish registry, 13 [2%] were due to herbals; none were due to resveratrol).</italic></p></annotation><pub-id pub-id-type="pmid">19159172</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.navarro.2009.373">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Navarro</surname>
<given-names>VJ</given-names></string-name>. <article-title>Herbal and dietary supplement hepatotoxicity.</article-title>
<source>Semin Liver Dis</source>
<year>2009</year>; <volume>29</volume>: <fpage>373</fpage>-<lpage>382</lpage>.<annotation><p><italic toggle="yes">(Overview of the regulatory environment, clinical patterns, and future directions in research with HDS; resveratrol is not listed as a potential hepatotoxin).</italic></p></annotation><pub-id pub-id-type="pmid">19826971</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.jacobsson.2009.1039">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jacobsson</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>J&#x000f6;nsson</surname>
<given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Gerd&#x000e9;n</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>H&#x000e4;gg</surname>
<given-names>S</given-names></string-name>. <article-title>Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden.</article-title>
<source>Pharmacoepidemiol Drug Saf</source>
<year>2009</year>; <volume>18</volume>: <fpage>1039</fpage>-<lpage>47</lpage>.<annotation><p><italic toggle="yes">(Review of 778 spontaneous reports of adverse reactions to herbals to Swedish Registry; no instance was linked to resveratrol).</italic></p></annotation><pub-id pub-id-type="pmid">19650152</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.almeida.2009.s7">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Almeida</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vaz-da-Silva</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Falc&#x000e3;o</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Soares</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Costa</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Loureiro</surname>
<given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Fernandes-Lopes</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal>
<article-title>Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.</article-title>
<source>Mol Nutr Food Res</source>
<year>2009</year>
<month>May</month>; <volume>53</volume>
<supplement>Suppl 1</supplement>: <fpage>S7</fpage>-<lpage>15</lpage>.<annotation><p><italic toggle="yes">(Pharmacokinetic study of 4 doses of resveratrol vs placebo given every 4 hours for 48 hours in 40 volunteers; side effects included headache, dyspepsia and dizziness; "no clinically significant abnormalities were found in the laboratory parameters").</italic></p></annotation><pub-id pub-id-type="pmid">19194969</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.brown.2010.9003">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Brown</surname>
<given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname>
<given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Viskaduraki</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Crowell</surname>
<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Perloff</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Booth</surname>
<given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Vasilinin</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal>
<article-title>Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.</article-title>
<source>Cancer Res</source>
<year>2010</year>; <volume>70</volume>: <fpage>9003</fpage>-<lpage>11</lpage>.<annotation><p><italic toggle="yes">(Pharmacokinetic study of 4 doses of resveratrol [0.5-4 gm daily] for 29 days in 40 volunteers found occasional minor abdominal discomfort, nausea, diarrhea, flatulence and dizziness with higher doses, but no serious adverse events).</italic></p></annotation><pub-id pub-id-type="pmid">20935227</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.reuben.2010.2065">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Reuben</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Koch</surname>
<given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>WM</given-names></string-name>; <collab>Acute Liver Failure Study Group</collab>. <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
<source>Hepatology</source>
<year>2010</year>; <volume>52</volume>: <fpage>2065</fpage>-<lpage>76</lpage>.<annotation><p><italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 [11%] were attributed to drug induced liver injury, of which 12 [9%] were due to herbals, including several herbal mixtures, usnic acid, Ma Huang, black cohosh, and Hydroxycut, but not resveratrol).</italic></p></annotation><pub-id pub-id-type="pmid">20949552</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.bishayee.2010.1103">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bishayee</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Darvesh</surname>
<given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Politis</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McGory</surname>
<given-names>R</given-names></string-name>. <article-title>Resveratrol and liver disease: from bench to bedside and community.</article-title>
<source>Liver Int</source>
<year>2010</year>; <volume>30</volume>: <fpage>1103</fpage>-<lpage>14</lpage>.<annotation><p><italic toggle="yes">(Extensive review of the in vitro and in vivo studies of resveratrol as a hepatoprotective agent against several forms of experimental liver injury, and the challenges of clinical studies of resveratrol in humans).</italic></p></annotation><pub-id pub-id-type="pmid">20557453</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.smoliga.2011.1129">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Smoliga</surname>
<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Baur</surname>
<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hausenblas</surname>
<given-names>HA</given-names></string-name>. <article-title>Resveratrol and health &#x02013; A comprehensive review of human clinical trials.</article-title>
<source>Mol Nutr Food Res</source>
<year>2011</year>; <volume>55</volume>: <fpage>1129</fpage>-<lpage>41</lpage>.<annotation><p><italic toggle="yes">(Review of the literature on pharmacokinetics, efficacy and safety of resveratrol in humans; few studies have been done, but none have reported severe adverse events or significant toxicities).</italic></p></annotation><pub-id pub-id-type="pmid">21688389</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.howells.2011.1419">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Howells</surname>
<given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname>
<given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Elliott</surname>
<given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Jacobson</surname>
<given-names>EW</given-names></string-name>, <string-name name-style="western"><surname>Hoffmann</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hegarty</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal>
<article-title>Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases&#x02014;safety, pharmacokinetics, and pharmacodynamics.</article-title>
<source>Cancer Prev Res (Phila)</source>
<year>2011</year>; <volume>4</volume>: <fpage>1419</fpage>-<lpage>25</lpage>.<annotation><p><italic toggle="yes">(9 subjects scheduled to undergo hepatectomy for cancer metastases were given a micronized resveratrol [5 gm/day] or placebo for 14 days; peak plasma levels were variable and achieved in 2-4 hours with plasma half-life of 1 hour, and detectable levels in tissue at surgery).</italic></p></annotation><pub-id pub-id-type="pmid">21680702</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.walle.2011.9">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Walle</surname>
<given-names>T.</given-names></string-name>
<article-title>Bioavailability of resveratrol.</article-title>
<source>Ann N Y Acad Sci</source>
<year>2011</year>; <volume>1215</volume>: <fpage>9</fpage>-<lpage>15</lpage>.<annotation><p><italic toggle="yes">(Resveratrol exists as trans and cis isomers and is well absorbed orally but is rapidly metabolized by intestine and liver to sulfate and glucuronide conjugates).</italic></p></annotation><pub-id pub-id-type="pmid">21261636</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.yoshino.2012.658">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yoshino</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Conte</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mittendorfer</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Imai</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schechtman</surname>
<given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kunz</surname>
<given-names>I</given-names></string-name>, <etal>et al.</etal>
<article-title>Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance.</article-title>
<source>Cell Metab</source>
<year>2012</year>; <volume>16</volume>: <fpage>658</fpage>-<lpage>64</lpage>.<annotation><p><italic toggle="yes">(Controlled study of resveratrol [75 mg/day] vs placebo in 29 normal volunteers, found no change in weight, insulin sensitivity, serum enzyme levels or in SIRT1 expression [in muscle and adipose tissue] or AMP-K activity [in muscle tissue] after 12 weeks of therapy).</italic></p></annotation><pub-id pub-id-type="pmid">23102619</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.teschke.2012.1543">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Teschke</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wolff</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Frenzel</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schulze</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eickhoff</surname>
<given-names>A.</given-names></string-name>
<article-title>Herbal hepatotoxicity: a tabular compilation of reported cases.</article-title>
<source>Liver Int</source>
<year>2012</year>; <volume>32</volume>: <fpage>1543</fpage>-<lpage>56</lpage>.<annotation><p><italic toggle="yes">(A systematic compilation of all publications on the hepatotoxicity of specific herbals identified 185 publications on 60 different herbs, herbal drugs and supplements; none implicated resveratrol).</italic></p></annotation><pub-id pub-id-type="pmid">22928722</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.navarro.2014.1399">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Navarro</surname>
<given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Barnhart</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bonkovsky</surname>
<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Davern</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Grant</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname>
<given-names>KR</given-names></string-name>, <etal>et al.</etal>
<article-title>Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network.</article-title>
<source>Hepatology</source>
<year>2014</year>; <volume>60</volume>:<fpage>1399</fpage>-<lpage>408</lpage>.<annotation><p><italic toggle="yes">(Among 85 cases of HDS associated liver injury enrolled in a US prospective study between 2004 and 2013, resveratrol was not implicated in any case).</italic></p></annotation><pub-id pub-id-type="pmid">25043597</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.chachay.2014.2092">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chachay</surname>
<given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>Macdonald</surname>
<given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname>
<given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Whitehead</surname>
<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>O'Moore-Sullivan</surname>
<given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Franklin</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Resveratrol does not benefit patients with nonalcoholic fatty liver disease.</article-title>
<source>Clin Gastroenterol Hepatol.</source>
<year>2014</year>;<volume>12</volume>:<fpage>2092</fpage>-<lpage>2103</lpage>.<annotation><p><italic toggle="yes">(Among 20 overweight or obese men with hepatic steatosis treated with resveratrol [1500 mg] or placebo twice daily for 8 weeks, there was no change in body weight, hepatic steatosis, fasting blood glucose or lipid levels, while serum ALT and AST increased [median ALT rising from 25 to 63 U/L, AST from 35 to 45 U/L], with minimal increases in serum bilirubin and cytokeratin 18 but no symptoms; these changes were attributed to the high doses used).</italic></p></annotation><pub-id pub-id-type="pmid">24582567</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.turner.2015.1383">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Turner</surname>
<given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname>
<given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Craft</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van Dyck</surname>
<given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Mintzer</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Reynolds</surname>
<given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Brewer</surname>
<given-names>JB</given-names></string-name>, <etal>et al</etal>; <collab>Alzheimer's Disease Cooperative Study</collab>. <article-title>A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.</article-title>
<source>Neurology</source>
<year>2015</year>; <volume>85</volume>: <fpage>1383</fpage>-<lpage>91</lpage>.<annotation><p><italic toggle="yes">(Among 119 patients with Alzheimer disease treated with resveratrol [500 mg increasing to as much as 2000 mg daily] vs placebo for 52 weeks, there was no improvement in clinical or radiologic features and adverse event rates were similar between the 2 groups; no mention of ALT levels except that "routine laboratory tests were normal").</italic></p></annotation><pub-id pub-id-type="pmid">26362286</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.yiu.2015.1344">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yiu</surname>
<given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Tai</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Peverill</surname>
<given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Croft</surname>
<given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Mori</surname>
<given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Scheiber-Mojdehkar</surname>
<given-names>B</given-names></string-name>, <etal>et al.</etal>
<article-title>An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.</article-title>
<source>J Neurol</source>
<year>2015</year>; <volume>262</volume>: <fpage>1344</fpage>-<lpage>53</lpage>.<annotation><p><italic toggle="yes">(Among 24 patients with Friedreich ataxia treated with resveratrol [1 gm vs 5 gm daily] for 12 weeks, adverse events more frequent with the higher dose included diarrhea [71% vs 8%], nausea [36% vs 8%] and skin rash [29% vs none], and 1 subject developed liver test abnormalities 4 weeks after starting high dose resveratrol [bilirubin not provided, ALT &#x0003c;2 times ULN, Alk P 4 times ULN], resolving 8 weeks after stopping).</italic></p></annotation><pub-id pub-id-type="pmid">25845763</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.chen.2015.226">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ran</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shu</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.</article-title>
<source>Dig Liver Dis</source>
<year>2015</year>; <volume>47</volume>: <fpage>226</fpage>-<lpage>32</lpage>.<annotation><p><italic toggle="yes">(Among 60 patients with nonalcoholic fatty liver disease treated with resveratrol [300 mg twice daily] vs placebo for 3 months, median ALT levels decreased by 7 vs 1 U/L in placebo recipients, while ultrasound graded hepatic fat did not change).</italic></p></annotation><pub-id pub-id-type="pmid">25577300</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.garc_acort_s.2016.537">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Garc&#x000ed;a-Cort&#x000e9;s</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Robles-D&#x000ed;az</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ortega-Alonso</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Medina-Caliz</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Andrade</surname>
<given-names>RJ</given-names></string-name>. <article-title>Hepatotoxicity by dietary supplements: A tabular listing and clinical characteristics.</article-title>
<source>Int J Mol Sci</source>
<year>2016</year>; <volume>17</volume>: <fpage>537</fpage>.<annotation><p><italic toggle="yes">(Listing of published cases of liver injury from HDS products, does not list resveratrol).</italic></p></annotation><pub-id pub-id-type="pmid">27070596</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.heeb_ll.2016.456">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Heeb&#x000f8;ll</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kreuzfeldt</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hamilton-Dutoit</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kj&#x000e6;r Poulsen</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>St&#x000f8;dkilde-J&#x000f8;rgensen</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>M&#x000f8;ller</surname>
<given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Jessen</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.</article-title>
<source>Scand J Gastroenterol.</source>
<year>2016</year>;<volume>51</volume>:<fpage>456</fpage>-<lpage>64</lpage>.<annotation><p><italic toggle="yes">(Among 28 adults with fatty liver and raised serum ALT levels treated with resveratrol [500 mg] or placebo 3 times daily for 6 months, there were no differences in changes in body weight, hepatic steatosis, blood glucose levels, lipids, and serum ALT and AST levels between the two arms; 1 treated patient developed fever and lymphopenia that resolved on stopping and recurred on restarting and another developed an asymptomatic rise in ALT levels [from 150 to ~380 U/L] that resolved despite continuing therapy).</italic></p></annotation><pub-id pub-id-type="pmid">26784973</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.brown.2017.472">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Brown</surname>
<given-names>AC</given-names></string-name>. <article-title>Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 2 of 5 series.</article-title>
<source>Food Chem Toxicol</source>
<year>2017</year>; <volume>107</volume>: <fpage>472</fpage>-<lpage>501</lpage>.<annotation><p><italic toggle="yes">(Description of an online compendium of cases of liver toxicity attributed to HDS products does not list or discuss resveratrol).</italic></p></annotation><pub-id pub-id-type="pmid">27402097</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.medinacaliz.2018.1495">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Medina-Caliz</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Garcia-Cortes</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez-Jimenez</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cabello</surname>
<given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Robles-Diaz</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sanabria-Cabrera</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sanjuan-Jimenez</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>; <collab>Spanish DILI Registry</collab>. <article-title>Herbal and dietary supplement-induced liver injuries in the Spanish DILI Registry.</article-title>
<source>Clin Gastroenterol Hepatol.</source>
<year>2018</year>;<volume>16</volume>:<fpage>1495</fpage>-<lpage>1502</lpage>.<annotation><p><italic toggle="yes">(Among 856 cases of hepatotoxicity enrolled in the Spanish DILI Registry between 1994 and 2016, 32 were attributed to herbal products, the most frequent cause being green tea [n=8] and Herbalife products [n=6], no mention of resveratrol).</italic></p></annotation><pub-id pub-id-type="pmid">29307848</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.asghari.2018.307">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Asghari</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rafraf</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Farzin</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Asghari-Jafarabadi</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ghavami</surname>
<given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Somi</surname>
<given-names>MH</given-names></string-name>. <article-title>Effects of pharmacologic dose of resveratrol supplementation on oxidative/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled Trial.</article-title>
<source>Adv Pharm Bull.</source>
<year>2018</year>;<volume>8</volume>:<fpage>307</fpage>-<lpage>317</lpage>.<annotation><p><italic toggle="yes">(Among 60 overweight or obese adults with nonalcoholic fatty liver treated with resveratrol [600 mg] or placebo daily for 12 weeks, there were no significant changes in markers of oxidative stress or in serum levels of ALT, AST, Alk P or GGT; no mention of adverse events or individual elevations in serum ALT or AST).</italic></p></annotation><pub-id pub-id-type="pmid">30023333</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.kantartzis.2018.1793">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kantartzis</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fritsche</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bombrich</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Machann</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schick</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Staiger</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kunz</surname>
<given-names>I</given-names></string-name>, <etal>et al.</etal>
<article-title>Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial.</article-title>
<source>Diabetes Obes Metab.</source>
<year>2018</year>;<volume>20</volume>:<fpage>1793</fpage>-<lpage>1797</lpage>.<annotation><p><italic toggle="yes">(Among 108 overweight or obese adults with fatty liver and insulin resistance treated with resveratrol [150 mg] or placebo daily for 12 weeks, there were no significant differences in changes in total, liver, or visceral fat [by magnetic resonance spectroscopy], fasting glucose or HbA1c levels, HOMA-IR, blood pressure, or liver enzymes levels between the two groups).</italic></p></annotation><pub-id pub-id-type="pmid">29484808</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.ballotin.2021.5490">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ballotin</surname>
<given-names>VR</given-names></string-name>, <string-name name-style="western"><surname>Bigarella</surname>
<given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Brand&#x000e3;o</surname>
<given-names>ABM</given-names></string-name>, <string-name name-style="western"><surname>Balbinot</surname>
<given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Balbinot</surname>
<given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Soldera</surname>
<given-names>J</given-names></string-name>. <article-title>Herb-induced liver injury: Systematic review and meta-analysis.</article-title>
<source>World J Clin Cases.</source>
<year>2021</year>;<volume>9</volume>:<fpage>5490</fpage>-<lpage>5513</lpage>.<annotation><p><italic toggle="yes">(Systematic review of the literature on herb induced liver injury identified 446 references describing 936 cases due to 79 different herbal products, the most common being He Shou Wu [91], green tea [90] Herbalife products [64], kava kava [62], and greater celandine [48]; no mention of resveratrol).</italic></p></annotation><pub-id pub-id-type="pmid">34307603</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.bessone.2022.e548">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bessone</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Garc&#x000ed;a-Cort&#x000e9;s</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Medina-Caliz</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hernandez</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Parana</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mendizabal</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schinoni</surname>
<given-names>MI</given-names></string-name>, <etal>et al.</etal>
<article-title>Herbal and dietary supplements-induced liver injury in Latin America: experience from the LATINDILI Network.</article-title>
<source>Clin Gastroenterol Hepatol.</source>
<year>2022</year>;<volume>20</volume>:<fpage>e548</fpage>-<lpage>e563</lpage>.<annotation><p><italic toggle="yes">(Among 367 cases of hepatotoxicity enrolled in the Latin American DILI Network between 2011 and 2019, 29 [8%] were attributed to herbal products, the most frequent being green tea [n=7], Herbalife products [n=5] and garcinia [n=3], while resveratrol was not mentioned).</italic></p></annotation><pub-id pub-id-type="pmid">33434654</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.kasprzakdrozd.2024.3746">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kasprzak-Drozd</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nizi&#x00144;ski</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kasprzak</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kondracka</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Oniszczuk</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rusinek</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Oniszczuk</surname>
<given-names>A</given-names></string-name>. <article-title>Does resveratrol improve metabolic dysfunction-associated steatotic liver disease (MASLD)?</article-title>
<source>Int J Mol Sci.</source>
<year>2024</year>;<volume>25</volume>:<fpage>3746</fpage>.<annotation><p><italic toggle="yes">(Resveratrol showed promising effects in vitro and in animal models of nonalcoholic steatohepatitis [NASH], possibly by inhibiting the NF-&#x003ba;B pathway, activating SIRT1 and AMP kinase, modifying the microbiome, or decreasing inflammation; but clinical studies &#x0201c;have yielded inconclusive results&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">38612556</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.keramatzadeh.2024.1">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Keramatzadeh</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hosseini</surname>
<given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Majdinasab</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Cheraghian</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zilaee</surname>
<given-names>M</given-names></string-name>. <article-title>Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.</article-title>
<source>Nutr Neurosci.</source>
<year>2024</year>:<fpage>1</fpage>-<lpage>9</lpage>. <comment>Epub ahead of print</comment>.<annotation><p><italic toggle="yes">(Among 55 patients with multiple sclerosis treated with resveratrol [500 mg] vs placebo daily for 8 weeks, there were significant decreases in serum malondialdehyde and tumor necrosis factor alpha levels with treatment but no significant changes in fatigue, food intake, body weight, lipids or glucose levels compared to placebo; no mention of adverse events, ALT levels, or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">39565038</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.ahmadimousavi.2024">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ahmadi-Mousavi</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Karami-Mohajeri</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dabaghzadeh</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Soltani</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Oghabian</surname>
<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sharifi</surname>
<given-names>H</given-names></string-name>. <article-title>The effects of resveratrol in a randomized clinical trial on drug-induced hyperlipidemia and psychiatric factors in people living with HIV.</article-title>
<source>Curr HIV Res.</source>
<year>2024</year>
<month>Nov</month>
<day>8</day>. <comment>Epub ahead of print</comment>.<annotation><p><italic toggle="yes">(Among 41 adults with HIV infection treated with resveratrol [500 mg] or placebo once daily for one month, there were no differences in changes in cholesterol or triglyceride levels or in symptoms or measures of quality of life and sleep quality; no mention of adverse events or ALT levels).</italic></p></annotation><pub-id pub-id-type="pmid">39528454</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.nguyen.2024.e1004440">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nguyen</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Coudeyre</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Boutron</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Baron</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Daste</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lef&#x000e8;vre-Colau</surname>
<given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Sellam</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL).</article-title>
<source>PLoS Med.</source>
<year>2024</year>;<volume>21</volume>:<elocation-id>e1004440</elocation-id>.<annotation><p><italic toggle="yes">(Among 142 patients with painful knee osteoarthritis treated with resveratrol [40 mg] or placebo twice daily for 6 months, there were no differences in knee pain between the two groups, and total and severe adverse events rates were similar, with none judged to be related to the intervention; no mention of ALT levels or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">39137167</pub-id>
</mixed-citation>
          </ref>
          <ref id="Resveratrol.REF.erol_do_an.2024.1504">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Erol Do&#x0011f;an</surname>
<given-names>&#x000d6;</given-names></string-name>, <string-name name-style="western"><surname>Karaca &#x000c7;elik</surname>
<given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Ba&#x0015f;</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alan</surname>
<given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>&#x000c7;a&#x0011f;&#x00131;n</surname>
<given-names>YF</given-names></string-name>. <article-title>Effects of Mediterranean diet, curcumin, and resveratrol on mild-to-moderate active ulcerative colitis: a multicenter randomized clinical trial.</article-title>
<source>Nutrients.</source>
<year>2024</year>;<volume>16</volume>:<fpage>1504</fpage>.<annotation><p><italic toggle="yes">(Among 48 patients with ulcerative colitis placed on a &#x0201c;Mediterranean diet&#x0201d; and treated with curcumin [1600 mg], resveratrol [500 mg] or placebo daily for 8 weeks, improvements in CRP and sedimentation rate and in health related quality of life and inflammatory bowel disease symptom scores occurred in all three groups with no additional effects in those receiving resveratrol or curcumin; no mention of adverse events or ALT levels).</italic></p></annotation><pub-id pub-id-type="pmid">38794742</pub-id>
</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Resveratrol.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <p>1. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Resveratrol/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Resveratrol: from PubMed.gov</ext-link></p>
        <p>2. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Resveratrol">Trials on Resveratrol: from ClinicalTrials.gov</ext-link></p>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
